Treatment of endometriosis-associated pain with linzagolix, an oral gonadotropin-releasing hormone–antagonist: a randomized clinical trial

Jacques Donnez, Donnez J, Taylor HS, Hugh S Taylor, Robert N Taylor, Taylor RN, Mark D Akin, Akin MD, Mark Akin, Т. Ф Татарчук, Tatyana F Tatarchuk, Wilk K, Krzysztof Wilk, Jean‐Pierre Gotteland, Jean-Pierre Gotteland, Gotteland JP, Lecomte V, Veronique Lecomte, V. Lecomte, Elke Bestel, Bestel E
Fertility and sterility · 2020 · vol. 114(1) , pp. 44–55 · doi:10.1016/j.fertnstert.2020.02.114 · PMID:32505383 · W3033596374
article OA: bronze CC0 ⤵ 70 in-corpus citations
🔓 Open OA copy View on OpenAlex View on PubMed View at publisher
⚙ AI-generated summary by claude@2026-06, 2026-06-06 ⓘ

This randomized clinical trial evaluated the efficacy and safety of linzagolix, an oral GnRH antagonist, for treating endometriosis-associated pain.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

Abstract

ObjectiveTo study the effect of a new investigational oral gonadotropin-releasing hormone antagonist, linzagolix, on endometriosis-associated pain (EAP).DesignA multinational, parallel group, randomized, placebo-controlled, double-blind, dose-ranging trial.SettingClinical centers.Patient(s)Women aged 18-45 years with surgically confirmed endometriosis and moderate-to-severe EAP.Intervention(s)The interventions were 50, 75, 100, or 200 mg linzagolix (or matching placebo) administered once daily for 24 weeks.Main outcome measure(s)The primary endpoint was the number of responders (≥30% reduction in overall pelvic pain) after 12 weeks. Other endpoints included dysmenorrhea, non-menstrual pelvic pain, serum estradiol, amenorrhea, quality of life (QoL) measures, and bone mineral density (BMD).Result(s)Compared with placebo, doses ≥ 75 mg resulted in a significantly greater proportion of responders for overall pelvic pain at 12 weeks (34.5%, 61.5%, 56.4%, and 56.3% for placebo, 75, 100, and 200 mg, respectively). A similar pattern was seen for dysmenorrhea and non-menstrual pelvic pain. The effects were maintained or increased at 24 weeks. Serum estradiol was suppressed, QoL improved, and the rate of amenorrhea increased in a dose-dependent fashion. Mean BMD loss (spine) at 24 weeks was <1% at doses of 50 and 75 mg and increased in a dose-dependent fashion up to 2.6% for 200 mg. BMD of femoral neck and total hip showed a similar pattern.Conclusion(s)Linzagolix significantly reduced EAP and improved QoL at doses of 75-200 mg and decreased BMD dose-dependently.Clinical trial registration numberNCT02778399.

My notes (saved in your browser only)

Condition tags

endometriosischronic_pelvic_pain

MeSH descriptors

Carboxylic Acids Carboxylic Acids Carboxylic Acids Chronic Pain Chronic Pain Chronic Pain Endometriosis Endometriosis Endometriosis Hormone Antagonists Hormone Antagonists Hormone Antagonists Pelvic Pain Pelvic Pain Pelvic Pain Pyrimidines Pyrimidines Pyrimidines Uterine Diseases Uterine Diseases

Citation neighborhood

Papers in the corpus that this work cites (lower rings, blue) and that cite this one (upper rings, green). Dot size scales with the paper's in-corpus citation count — bigger dot = more influential within the endo/adeno field. Click a dot to open that paper. [ expand to 2 hops ] — adds papers reached through this work's immediate citers/citees. Heavier; up to 60 extra dots.

References (32)

Cited by (50)

Source provenance

europepmc
last seen: 2026-07-29T06:27:48.050232+00:00
openalex
last seen: 2026-06-10T17:14:06.276822+00:00
pubmed
last seen: 2026-05-13T22:21:59.141895+00:00
License: CC0 · commercial use OK